Cholesterol- lowering drug given cancer all-clear

Cholesterol- lowering drug given cancer all-clear


Cancer fears about a cholesterol- lowering drug have turned out to be a 'statistical blip'. A class of cholesterol- lowering drug that had been implicated in a cancer scare has been cleared by epidemiologists using the results from two large ongoing clinical trials.

 
Preliminary results from the relatively small SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study had triggered the cancer scare in July. The trial was designed to investigate whether a combination of these two cholesterol- lowering drugs would help in cases of aortic stenosis, where a key heart valve is partially blocked.

Simvastatin, a statin that has already been used in other drugs, works by blocking cholesterol synthesis in the body. The newer ezetimibe works by blocking the absorption of cholesterol from the gut. 

A unusual pre-publication announcement from the SEAS study reported that, while the therapy did not help very much in aortic stenosis, cancer appeared more frequently in the treated groups.

Comments

Popular posts from this blog

 Role of Blockchain in Healthcare Data Management

Demystifying AI in Drug Discovery: Transforming Pharma R&D